Sonic Healthcare Limited (ASX:SHL)
Australia
· Delayed Price · Currency is AUD | Market Cap | 9.97B |
| Revenue (ttm) | 10.42B |
| Net Income (ttm) | 539.40M |
| Shares Out | 494.08M |
| EPS (ttm) | 1.11 |
| PE Ratio | 18.26 |
| Forward PE | 15.69 |
| Dividend | 1.07 (5.30%) |
| Ex-Dividend Date | Mar 4, 2026 |
| Volume | 416,133 |
| Average Volume | 1,593,252 |
| Open | 20.12 |
| Previous Close | 20.18 |
| Day's Range | 19.95 - 20.25 |
| 52-Week Range | 18.88 - 29.24 |
| Beta | 0.61 |
| RSI | 42.62 |
| Earnings Date | May 19, 2026 |
About Sonic Healthcare
Sonic Healthcare Limited offers medical diagnostic services, and administrative services and facilities to medical practitioners in Australia, the United States, Germany, and internationally. The company provides laboratory medicine/pathology testing services, such as biochemistry, cytopathology, genetics, haematology, histopathology, immunoserology, microbiology, molecular pathology, prenatal testing, toxicology, and ancillary functions; and radiology services, including magnetic resonance imaging, computed tomography (CT), ultrasound, X-ray, ... [Read more]
Financial Performance
In fiscal year 2025, Sonic Healthcare's revenue was 9.65 billion, an increase of 7.56% compared to the previous year's 8.97 billion. Earnings were 513.60 million, an increase of 0.49%.
Financial StatementsNews
Sonic Healthcare Earnings Call Transcript: H1 2026
Revenue grew 5% organically in H1 FY2026, with strong results in Australia, Germany, and the UK. EBITDA margin improved, guidance was reaffirmed, and capital management initiatives—including property sales and potential buybacks—are underway.
Sonic Healthcare Transcript: AGM 2025
The meeting marked a major leadership transition, reviewed solid financial results, and reaffirmed a focus on medical leadership, sustainability, and disciplined growth. Shareholders approved all resolutions and received updates on acquisitions, dividends, and ongoing strategic priorities.
Sonic Healthcare Earnings Call Transcript: H2 2025
Revenue and EBITDA both grew 8% year-over-year, with strong cash generation and margin expansion. FY 2026 guidance anticipates up to 19% EPS growth, driven by organic growth and recent acquisitions, while integration and synergy capture are underway across key geographies.
Sonic Healthcare Earnings Call Transcript: H1 2025
Strong half-year results with 8% revenue and 17% net profit growth, driven by organic expansion, cost control, and recent acquisitions. Margin expansion and robust cash flow support positive guidance, with major synergies expected from the Kramer Group acquisition and ongoing operational improvements.
Sonic Healthcare Transcript: AGM 2024
The meeting highlighted strong base business growth, ongoing integration of major acquisitions, and a continued focus on digital and AI-driven transformation. All resolutions passed, with board renewal and cost management initiatives set to drive future margin and earnings improvements.
Sonic Healthcare Earnings Call Transcript: H2 2024
FY 2024 saw strong organic growth, major acquisitions, and a return to margin expansion, with EBITDA of AUD 1.602 billion and a 2% dividend increase. Guidance for FY 2025 targets up to 10% EBITDA growth, supported by easing inflation and integration of recent acquisitions.